May 9th 2024
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
A retrospective study revealed an increase in the incidence of colorectal cancer in patients <50 years across all income brackets and demographic groups, according to investigators from The University of Texas at Austin Dell Medical School. The findings were presented at the 2019 Gastrointestinal Cancers Symposium.
Read More
Polymorphisms May Offer Promising Biomarkers to Predict Outcomes in Colorectal Cancer
April 9th 2019Although biomarker discovery has been a challenge in colorectal cancer, new findings suggest the presence of select polymorphisms may be promising in predicting treatment outcomes in patients with colorectal cancer.
Read More
Patient Misconceptions About Clinical Trials Are a Common Source of Resistance, Expert Panel Says
April 8th 2019Before a community oncology practice considers getting involved in clinical trials research, there are many factorsto consider. Perhaps foremost is the fact that cancer clinical trials provide the evidence base for new advances in oncology.
Read More
Despite Slow Adoption, Artificial Intelligence Pilot Programs Yield Practical Results
April 6th 2019Artificial intelligence has made inroads in many industries—banking, finance, security—but its adoption in healthcare has been lagging and real-world clinical implementation has yet to become a reality. Nonetheless, proponents say it is only a matter of time and pilot programs are starting to yield some practical results.
Read More
Frontline FOLFOXIRI Plus Bevacizumab Effective in Metastatic Colorectal Cancer
March 22nd 2019The combination of FOLFOXIRI plus molecular targeted therapies, including bevacizumab, was effective as a first-line treatment in metastatic colorectal cancer, according to findings from a retrospective study recently published in <em>Oncotarget.</em>
Read More
NCCN Updates Guidelines for BRAF-Mutant CRC to Include Triplet With Encorafenib And Binimetinib
March 19th 2019The clinical practice guidelines for the treatment of patients with colorectal cancer have been updated by NCCN to include the combination of encorafenib plus binimetinib in addition to EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with <em>BRAF</em> V600E–mutant metastatic CRC, after 1 or 2 prior therapies for metastatic disease.
Read More
CMS Mulls Opposition to Downsizing Part D Protected Drug Classes
March 15th 2019The healthcare community is still awaiting a response from the Centers for Medicare & Medicaid Services to the opposition of the agency’s proposal to substantially revise the Medicare Part D protected drug classes.
Read More
Avoiding Overtreatment Saves Medicare $320M Over 3-Year Period in Older Men With Prostate Cancer
March 13th 2019Overtreating men 70 years or older with prostate cancer cost Medicare more than $1.2 billion from 2004 to 2007, according to the results of a retrospective study using the Surveillance, Epidemiology, and End Results–Medicare linked database.
Read More
Focusing On Optimal Settings for Selective Internal Radiation Therapy in CRC With Liver Mets
March 12th 2019In an interview with <em>Targeted Therapies in Oncology</em>, Michael Cusnir, MD, explained that Y-90 is a type of beta emitter that is extremely focused, which allows for the treatment to be localized without affecting healthy portions of the liver or other structures surrounding the liver; it is delivered to selectively embolize the liver.
Read More
Younger Patients With CRC Likely to Face Misdiagnosis, Late-Stage Diagnosis
March 6th 2019The majority of younger patients ultimately diagnosed with colorectal cancer waited 3 to 12 months to see a doctor after symptoms began and were commonly misdiagnosed with issues such as hemorrhoids, irritable bowel syndrome, and anemia, according to recent findings.
Read More